tetano
Editor, Senior Moderator
J Infect Dis
. 2021 Sep 20;jiab482.
doi: 10.1093/infdis/jiab482. Online ahead of print.
Plasma from post-COVID-19 and COVID-19-Vaccinated Donors Results in Highly Potent SARS-CoV-2 Neutralization by Intravenous Immunoglobulins
Michael Karbiener[SUP] 1 [/SUP], Maria R Farcet[SUP] 1 [/SUP], Julia Schwaiger[SUP] 1 [/SUP], Nicholas Powers[SUP] 2 [/SUP], James Lenart[SUP] 2 [/SUP], Joseph M Stewart[SUP] 2 [/SUP], Hema Tallman[SUP] 2 [/SUP], Thomas R Kreil[SUP] 1 [/SUP]
Affiliations
Abstract
From September 2020, some immunoglobulin (IG) lots from US plasma contained neutralizing antibodies against the newly emerged SARS-CoV-2. Paralleled by the increasing numbers of post-COVID-19 donors, IG lot antibody positivity increased to 93% by January 2021, at a mean titer of ~30 IU/mL. The correlation predicted anti-SARS-CoV-2 potency to reach 345 IU/mL by July 2021. In addition to post-COVID-19 donors, the rapidly increasing number of COVID-19 vaccinated plasma donors now result in a mean antibody titer of >600 IU/mL already in July 2021 IG lots, with SARS-CoV-2 antibody titers for several lots even higher than earlier produced hyperimmune globulin products.
Keywords: COVID-19; CoVIg-19; Primary immunodeficiency; SARS coronavirus 2 antibody potency; SARS-CoV-2; Secondary immunodeficiency; hyperimmune globulin; immunoglobulin; intravenous immune globulin; neutralizing antibodies; plasma; prophylaxis.
. 2021 Sep 20;jiab482.
doi: 10.1093/infdis/jiab482. Online ahead of print.
Plasma from post-COVID-19 and COVID-19-Vaccinated Donors Results in Highly Potent SARS-CoV-2 Neutralization by Intravenous Immunoglobulins
Michael Karbiener[SUP] 1 [/SUP], Maria R Farcet[SUP] 1 [/SUP], Julia Schwaiger[SUP] 1 [/SUP], Nicholas Powers[SUP] 2 [/SUP], James Lenart[SUP] 2 [/SUP], Joseph M Stewart[SUP] 2 [/SUP], Hema Tallman[SUP] 2 [/SUP], Thomas R Kreil[SUP] 1 [/SUP]
Affiliations
- PMID: 34543421
- DOI: 10.1093/infdis/jiab482
Abstract
From September 2020, some immunoglobulin (IG) lots from US plasma contained neutralizing antibodies against the newly emerged SARS-CoV-2. Paralleled by the increasing numbers of post-COVID-19 donors, IG lot antibody positivity increased to 93% by January 2021, at a mean titer of ~30 IU/mL. The correlation predicted anti-SARS-CoV-2 potency to reach 345 IU/mL by July 2021. In addition to post-COVID-19 donors, the rapidly increasing number of COVID-19 vaccinated plasma donors now result in a mean antibody titer of >600 IU/mL already in July 2021 IG lots, with SARS-CoV-2 antibody titers for several lots even higher than earlier produced hyperimmune globulin products.
Keywords: COVID-19; CoVIg-19; Primary immunodeficiency; SARS coronavirus 2 antibody potency; SARS-CoV-2; Secondary immunodeficiency; hyperimmune globulin; immunoglobulin; intravenous immune globulin; neutralizing antibodies; plasma; prophylaxis.